BiotechTube

ceftobiprole medocaril

Phase 2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bacteremia

Conditions

Bacteremia

Trial Timeline

— → Apr 1, 2009

NCT ID
NCT00505258

About ceftobiprole medocaril

ceftobiprole medocaril is a phase 2 stage product being developed by Basilea Pharmaceutica for Bacteremia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00505258. Target conditions include Bacteremia.

What happened to similar drugs?

2 of 5 similar drugs in Bacteremia were approved

Approved (2) Terminated (3) Active (1)
✅Daptomycin + ComparatorMerckApproved
✅Vancomycin + DaptomycinMerckApproved
❌Ceftolozane-Tazobactam + MeropenemMerckPhase 3
❌Cefazolin IV + Linezolid IV + Vancomycin (IV)PfizerPhase 3
🔄Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00505258Phase 2Withdrawn
NCT05856227Phase 3Completed
NCT02527681Phase 1Terminated

Competing Products

9 competing products in Bacteremia

See all competitors
ProductCompanyStageHype Score
Daptomycin + ComparatorMerckApproved
43
Daptomycin for InjectionMerckPhase 2
35
Vancomycin + DaptomycinMerckApproved
35
Ceftolozane-Tazobactam + MeropenemMerckPhase 3
32
Cefazolin IV + Linezolid IV + Vancomycin (IV)PfizerPhase 3
32
Aurexis®Bristol Myers SquibbPhase 2
35
Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3
34
AP-SA02Armata PharmaceuticalsPhase 1/2
22
514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase IIXBiotechPhase 1/2
22